Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

9 Apr 2020

Abstract excerpt

Dysregulated activation of the MET tyrosine kinase receptor is implicated in the development of solid tumors and can arise through several mechanisms, including gene amplification, overexpression of the receptor and/or its ligand hepatocyte growth factor (HGF), and the acquisition of activating mutations. The most common activating mutations cause exon 14 to be skipped during MET mRNA splicing. This in-frame...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatocellular Carcinoma Treatment and Prognosis
Share to Liver physiology and pathology

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32334240
DOI: 10.1016/j.ctrv.2020.102022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skippingPMID 32334240Read ↗

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant diseaseSemantic proximity Read ↗

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-LifeSemantic proximity Read ↗

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.Semantic proximity Read ↗

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.